Patents Examined by Elizabeth C. Kemmerer
  • Patent number: 10802026
    Abstract: The present invention provides reagents and methods for breast cancer detection.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 13, 2020
    Assignees: Arizona Board of Regents, a Body Corporate acting for and on behalf of Arizona State University, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Joshua Labaer, Karen Sue Anderson, Garrick Wallstrom, Sahar Sibani, Niroshan Ramachandran
  • Patent number: 10792338
    Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 6, 2020
    Assignee: Remedor Biomed Ltd.
    Inventor: Saher Hamed
  • Patent number: 10781251
    Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: September 22, 2020
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jörg Wischhusen, Markus Junker, Thomas Müller, Stefan Saremba
  • Patent number: 10774153
    Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: September 15, 2020
    Assignees: UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Marcel Blot-Chabaud, Karim Harhouri, Nathalie Bardin, Benjamin Guillet, Francoise Dignat-George
  • Patent number: 10774145
    Abstract: The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: September 15, 2020
    Assignee: Allakos Inc.
    Inventors: Christopher Robert Bebbington, Nenad Tomasevic, Rustom Falahati, Bradford Andrew Youngblood
  • Patent number: 10774132
    Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: September 15, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITTUE
    Inventors: Vaughn Smider, Omar A. Bazirgan, Hongyuan Helen Mao, Peter Schultz, Feng Wang, Yong Zhang
  • Patent number: 10772955
    Abstract: The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 15, 2020
    Assignee: ARLA FOODS AMBA
    Inventors: Anne Staudt Kvistgaard, Peter Langborg Wejse, Sharon Donovan, Marcia H. Monaco Siegel, Sarah S. Comstock
  • Patent number: 10759871
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 1, 2020
    Assignee: SANOFI
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Patent number: 10736942
    Abstract: Compositions and methods for inducing or promoting repair of a bone fracture.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 11, 2020
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Fariba Dehghani, Ali Fathi, Suzanne Marie Mithieux, Anthony Steven Weiss
  • Patent number: 10736988
    Abstract: The invention relates to peptides including DEDE(SSD)nDEG indicated by SEQ NO. 1, RRRDEDE(SSD)nDEG indicated by SEQ NO. 2, RRRGDEDE(SSD)nDEG indicated by SEQ NO. 3, and LKKLKKLDEDE(SSD)nDEG indicated by SEQ NO. 4, wherein n is an integer from 2 to 20. The invention also relates to phosphorylating these peptides at multiple amino acid sites by employing casein kinases. These phosphorylated peptides may be used in various applications such as forming mineralized collagen fibrils and biomimetic composites for use in tissue repair and regeneration.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: August 11, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Elia Beniash, Charles S. Sfeir
  • Patent number: 10738095
    Abstract: The present invention provides a CCL20 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of psoriasis, inflammatory disorders and autoimmune disease.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: August 11, 2020
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian F. Volkman, Anthony E. Getschman, Sam T. Hwang, Yasutomo Imai, Francis C. Peterson
  • Patent number: 10722558
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: July 28, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, John Knopf
  • Patent number: 10723800
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 28, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda
  • Patent number: 10723775
    Abstract: The present invention relates to a method for purifying darbepoetin alfa by selectively separating only a structural isoform having a high content of sialic acid from a mixture of structural isoforms of darbepoetin alfa having various contents of sialic acid. Since the method of the present invention is a novel method for purifying darbepoetin alfa which can be conveniently and simply produced, it is possible to remarkably increase productivity due to process efficiency improvement, as well as to yield high purity darbepoetin alfa when mass-producing darbepoetin alfa according to the present invention.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: July 28, 2020
    Assignee: CJ Healthcare Corporation
    Inventors: Yoon Jung Lee, Kyung Hwa Kim, Yoo Hee Yang, Jung Min Yoo, Se Jun Kim, Ji Hyun Moon, Hoo Keun Oh, Dong Eok Lee, Won Jeong Lee, Jung Rok Lee, Chung Min Lee, Eun Young Choi, Gyong Sik Ha
  • Patent number: 10711052
    Abstract: The present invention discloses a method for treating wounds and for accelerating the healing of wounds by administering an effective amount of a pharmaceutical composition containing type VII collagen protein, mini-C7 protein, variants thereof or any combinations thereof. The pharmaceutical composition may be administered through a variety of routes including intravenous injection, topical application, or oral ingestion. The method may further include administering a genetically modified fibroblast capable of expressing type VII collagen protein, mini-C7 protein, variants thereof or small growth factors to achieve synergistic healing effect.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: July 14, 2020
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Mei Chen, David Woodley
  • Patent number: 10702583
    Abstract: The present invention provides methods and compositions for expanding T regulatory cells ex vivo or in vivo using one or more SAP agonists. The methods and compositions are useful in the treatment of autoimmune diseases and in preventing foreign graft rejection.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: July 7, 2020
    Assignee: Promedior, Inc.
    Inventor: Lynne Anne Murray
  • Patent number: 10695405
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: June 30, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, John Knopf
  • Patent number: 10683346
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof to human BMP6 and compositions and methods of use thereof.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: June 16, 2020
    Assignee: Novartis AG
    Inventors: Feng Cong, William Dietrich, Nathalie George, Dong Liu, Asher Schachter, Aditi Soni, Jing Zhou
  • Patent number: 10669312
    Abstract: The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-?B and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN).
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: June 2, 2020
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong-Ji Chung, Eun-Mi Kim, Eung-Ji Lee, Tae-Hoon Lee, A-Reum Han
  • Patent number: 10668154
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: June 2, 2020
    Assignee: Amgen Inc.
    Inventors: Tiansheng Li, Christopher James Sloey